Shots:

• The approval is based on P-lll ATTRACTION-3 study involve the assessment of Opdivo vs CT (docetaxel or paclitaxel) for patients with esophageal cancer refractory/ intolerant to 1L combination therapy with fluoropyrimidine- and Pt.-based drugs
• Results: reduction in risk of death (23%); m-OS (10.9 vs 8.4 mos.); @12 & 18-mos. OS rates (47% & 31% vs 34% & 21%); ORR (19% and 22%); DoR (6.9 vs 3.9 mos.)
• Opdivo is a PD-1 immune checkpoint inhibitor- designed to harness the body’s immune system to help restore anti-tumor immune response and is the first immunotherapy to be approved for gastroesophageal cancer in the EU

 ­ Ref: Bristol Myers Squibb | Image: Bristol Myers Squibb